NCT03260803View on ClinicalTrials.gov

Oligopin Supplementation and Bone Turnover Markers and Antioxidant Changes in Postmenopausal Osteopenic Women

PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

December 1, 2018

Study Completion Date

March 1, 2019

Conditions
Osteopenia
Interventions
DRUG

Oligopin

Oligopin ,150 mg ,once daily, 12 week

DRUG

Placebo

Placebo,150 mg ,once daily, 12 week

Trial Locations (1)

0098

Tehran University of Medical Sciences, Tehran

All Listed Sponsors
collaborator

Iran University of Medical Sciences

OTHER

lead

Tehran University of Medical Sciences

OTHER

NCT03260803 - Oligopin Supplementation and Bone Turnover Markers and Antioxidant Changes in Postmenopausal Osteopenic Women | Biotech Hunter | Biotech Hunter